Selenium Action in Neuro-Oncology

Biological Trace Element Research

Volumn 161, Issue 3, 2014, Pages 246-254

  Yakubov, Eduard ^a   Buchfelder, Michael ^a   Eyüpoglu, Ilker Y ^a   Savaskan, Nic E ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

Alternative therapy; Brain tumor; Clinical trial; Glioblastoma; Novel chemotherapeutic compounds; Vascular endothelial growth factor

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; SELENIUM; TEMOZOLOMIDE; ANTINEOPLASTIC AGENT; SELENOPROTEIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BRAIN TUMOR; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PREVENTION; DRUG EFFICACY; DRUG MECHANISM; GENOTOXICITY; GLIOBLASTOMA; GLIOMA; HUMAN; LIVER PROTECTION; LIVER TOXICITY; NEPHROTOXICITY; NONHUMAN; RENAL PROTECTION; TUMOR MICROENVIRONMENT; APOPTOSIS; BRAIN NEOPLASMS; DEFICIENCY; DRUG EFFECTS; METABOLISM; PATHOLOGY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BRAIN NEOPLASMS; GLIOBLASTOMA; HUMANS; SELENIUM; SELENOPROTEINS;

EID: 84919921789     PISSN: 01634984     EISSN: 15590720     Source Type: Journal    
DOI: 10.1007/s12011-014-0111-8     Document Type: Article

References (102)

1. Brauer AU, Savaskan NE (2004) Molecular actions of selenium in the brain: Neuroprotective mechanisms of an essential trace element. Rev Neurosci 15(1):19–32
2. Schweizer U, Brauer AU, Kohrle J, Nitsch R, Savaskan NE (2004) Selenium and brain function: a poorly recognized liaison. Brain Res Brain Res Rev 45(3):164–178
3. Pillai R, Uyehara-Lock JH, Bellinger FP (2014) Selenium and selenoprotein function in brain disorders. IUBMB Life 66(4):229–239
4. Byrns CN, Pitts MW, Gilman CA, Hashimoto AC, Berry MJ (2014) Mice lacking selenoprotein P and selenocysteine lyase exhibit severe neurological dysfunction, neurodegeneration, and audiogenic seizures. J Biol Chem 289(14):9662–9674
5. Bleys J, Navas-Acien A, Guallar E (2008) Serum selenium levels and all-cause, cancer, and cardiovascular mortality among US adults. Arch Intern Med 168(4):404–410
6. Ray AL, Semba RD, Walston J et al (2006) Low serum selenium and total carotenoids predict mortality among older women living in the community: the women's health and aging studies. J Nutr 136(1):172–176
7. Carlson BA, Yoo MH, Shrimali RK et al (2010) Role of selenium-containing proteins in T-cell and macrophage function. Proc Nutr Soc 69(3):300–310
8. Hall JA, Vorachek WR, Stewart WC et al (2013) Selenium supplementation restores innate and humoral immune responses in footrot-affected sheep. PLoS One 8(12):e82572
9. Naziroglu M, Senol N, Ghazizadeh V, Yuruker V (2014) Neuroprotection induced by N-acetylcysteine and selenium against traumatic brain injury-induced apoptosis and calcium entry in hippocampus of rat. Cell Mol Neurobiol 34(6):895–903
10. Streicher KL, Sylte MJ, Johnson SE, Sordillo LM (2004) Thioredoxin reductase regulates angiogenesis by increasing endothelial cell-derived vascular endothelial growth factor. Nutr Cancer 50(2):221–231
11. Kristal AR, Darke AK, Morris JS et al (2014) Baseline selenium status and effects of selenium and vitamin E supplementation on prostate cancer risk. J Natl Cancer Inst 106(3):djt456
12. Clark LC, Combs GF Jr, Turnbull BW et al (1996) Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA 276(24):1957–1963
13. Clark LC, Dalkin B, Krongrad A et al (1998) Decreased incidence of prostate cancer with selenium supplementation: Results of a double-blind cancer prevention trial. Br J Urol 81(5):730–734
14. Duffield-Lillico AJ, Reid ME, Turnbull BW et al (2002) Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: a summary report of the Nutritional Prevention of Cancer Trial. Cancer Epidemiol Biomarkers Prev 11(7):630–639
15. Wen PY, Kesari S (2008) Malignant gliomas in adults. N Engl J Med 359(5):492–507
16. Ip C, Thompson HJ, Zhu Z, Ganther HE (2000) In vitro and in vivo studies of methylseleninic acid: evidence that a monomethylated selenium metabolite is critical for cancer chemoprevention. Cancer Res 60(11):2882–2886
17. Qi Y, Fu X, Xiong Z et al (2012) Methylseleninic acid enhances paclitaxel efficacy for the treatment of triple-negative breast cancer. PLoS One 7(2):e31539
18. Ganther HE (1999) Selenium metabolism, selenoproteins and mechanisms of cancer prevention: complexities with thioredoxin reductase. Carcinogenesis 20(9):1657–1666
19. Ganther HE (1971) Reduction of the selenotrisulfide derivative of glutathione to a persulfide analog by glutathione reductase. Biochemistry 10(22):4089–4098
20. Husain K, Morris C, Whitworth C, Trammell GL, Rybak LP, Somani SM (1998) Protection by ebselen against cisplatin-induced nephrotoxicity: Antioxidant system. Mol Cell Biochem 178(1–2):127–133
21. Itoh M, Suzuki KT (1997) Effects of dose on the methylation of selenium to monomethylselenol and trimethylselenonium ion in rats. Arch Toxicol 71(7):461–466
22. Papp LV, Lu J, Holmgren A, Khanna KK (2007) From selenium to selenoproteins: Synthesis, identity, and their role in human health. Antioxid Redox Signal 9(7):775–806
23. Patterson BH, Zech LA (1992) Development of a model for selenite metabolism in humans. J Nutr 122(3 Suppl):709–714
24. Kryukov GV, Castellano S, Novoselov SV et al (2003) Characterization of mammalian selenoproteomes. Science 300(5624):1439–1443
25. Loscalzo J (2014) Keshan disease, selenium deficiency, and the selenoproteome. N Engl J Med 370(18):1756–1760
26. Castellano S, Lobanov AV, Chapple C et al (2005) Diversity and functional plasticity of eukaryotic selenoproteins: Identification and characterization of the SelJ family. Proc Natl Acad Sci U S A 102(45):16188–16193
27. Savaskan NE, Borchert A, Brauer AU, Kuhn H (2007) Role for glutathione peroxidase-4 in brain development and neuronal apoptosis: Specific induction of enzyme expression in reactive astrocytes following brain injury. Free Radic Biol Med 43(2):191–201
28. Savaskan NE, Ufer C, Kuhn H, Borchert A (2007) Molecular biology of glutathione peroxidase 4: from genomic structure to developmental expression and neural function. Biol Chem 388(10):1007–1017
29. Ufer C, Wang CC, Fahling M et al (2008) Translational regulation of glutathione peroxidase 4 expression through guanine-rich sequence-binding factor 1 is essential for embryonic brain development. Genes Dev 22(13):1838–1850
30. Beckett GJ, Arthur JR (2005) Selenium and endocrine systems. J Endocrinol 184(3):455–465
31. Battin EE, Brumaghim JL (2009) Antioxidant activity of sulfur and selenium: a review of reactive oxygen species scavenging, glutathione peroxidase, and metal-binding antioxidant mechanisms. Cell Biochem Biophys 55(1):1–23
32. Uden PC, Bird SM, Kotrebai M et al (1998) Analytical selenoamino acid studies by chromatography with interfaced atomic mass spectrometry and atomic emission spectral detection. Fresenius J Anal Chem 362(5):447–456
33. Trepanier G, Furling D, Puymirat J, Mirault ME (1996) Immunocytochemical localization of seleno-glutathione peroxidase in the adult mouse brain. Neuroscience 75(1):231–243
34. Zhang Y, Zhou Y, Schweizer U et al (2008) Comparative analysis of selenocysteine machinery and selenoproteome gene expression in mouse brain identifies neurons as key functional sites of selenium in mammals. J Biol Chem 283(4):2427–2438
35. Hill KE, Zhou J, McMahan WJ et al (2003) Deletion of selenoprotein P alters distribution of selenium in the mouse. J Biol Chem 278(16):13640–13646
36. Schomburg L, Schweizer U, Holtmann B, Flohe L, Sendtner M, Kohrle J (2003) Gene disruption discloses role of selenoprotein P in selenium delivery to target tissues. Biochem J 370(Pt 2):397–402
37. Saijoh K, Saito N, Lee MJ, Fujii M, Kobayashi T, Sumino K (1995) Molecular cloning of cDNA encoding a bovine selenoprotein P-like protein containing 12 selenocysteines and a (His-Pro) rich domain insertion, and its regional expression. Brain Res Mol Brain Res 30(2):301–311
38. Yan J, Barrett JN (1998) Purification from bovine serum of a survival-promoting factor for cultured central neurons and its identification as selenoprotein-P. J Neurosci 18(21):8682–8691
39. Scharpf M, Schweizer U, Arzberger T, Roggendorf W, Schomburg L, Kohrle J (2007) Neuronal and ependymal expression of selenoprotein P in the human brain. J Neural Transm 114(7):877–884
40. Raman AV, Pitts MW, Seyedali A et al (2012) Absence of selenoprotein P but not selenocysteine lyase results in severe neurological dysfunction. Genes Brain Behav 11(5):601–613
41. Hill KE, Wu S, Motley AK et al (2012) Production of selenoprotein P (Sepp1) by hepatocytes is central to selenium homeostasis. J Biol Chem 287(48):40414–40424
42. Kurokawa S, Hill KE, McDonald WH, Burk RF (2012) Long isoform mouse selenoprotein P (Sepp1) supplies rat myoblast L8 cells with selenium via endocytosis mediated by heparin binding properties and apolipoprotein E receptor-2 (ApoER2). J Biol Chem 287(34):28717–28726
43. Ellis DR, Salt DE (2003) Plants, selenium and human health. Curr Opin Plant Biol 6(3):273–279
44. Reid ME, Duffield-Lillico AJ, Slate E et al (2008) The nutritional prevention of cancer: 400 mcg per day selenium treatment. Nutr Cancer 60(2):155–163
45. Wallace K, Kelsey KT, Schned A, Morris JS, Andrew AS, Karagas MR (2009) Selenium and risk of bladder cancer: a population-based case–control study. Cancer Prev Res 2(1):70–73
46. Tan JA, An WY, Li RB (1987) The geo-medical characteristics of Keshan disease. Keshan disease prevention and treatment in China, pp 254–264
47. Philipov P, Tzatchev K (1988) Selenium concentrations in serum of patients with cerebral and extracerebral tumors. Zentralbl Neurochir 49(4):344–347
48. DeAngelis LM (2001) Brain tumors. N Engl J Med 344(2):114–123
49. Brat DJ, Castellano-Sanchez AA, Hunter SB et al (2004) Pseudopalisades in glioblastoma are hypoxic, express extracellular matrix proteases, and are formed by an actively migrating cell population. Cancer Res 64(3):920–927
50. Giannelli G, Falk-Marzillier J, Schiraldi O, Stetler-Stevenson WG, Quaranta V (1997) Induction of cell migration by matrix metalloprotease-2 cleavage of laminin-5. Science 277(5323):225–228
51. Rooprai HK, Kyriazis I, Nuttall RK et al (2007) Inhibition of invasion and induction of apoptosis by selenium in human malignant brain tumour cells in vitro. Int J Oncol 30(5):1263–1271
52. Roomi MW, Ivanov V, Kalinovsky T, Niedzwiecki A, Rath M (2007) Inhibition of glioma cell line A-172 MMP activity and cell invasion in vitro by a nutrient mixture. Med Oncol 24(2):231–238
53. Yoon SO, Kim MM, Chung AS (2001) Inhibitory effect of selenite on invasion of HT1080 tumor cells. J Biol Chem 276(23):20085–20092
54. Sarkar FH, Li Y (2006) Using chemopreventive agents to enhance the efficacy of cancer therapy. Cancer Res 66(7):3347–3350
55. Uğuz AC, Naziroğlu M, Espino J et al (2009) Selenium modulates oxidative stress-induced cell apoptosis in human myeloid HL-60 cells through regulation of calcium release and caspase-3 and −9 activities. J Membr Biol 232:15–23
56. Kahya MC, Nazıroğlu M, Ciğ B (2014) Selenium reduces mobile phone (900 MHz)-induced oxidative stress, mitochondrial function, and apoptosis in breast cancer cells. Biol Trace Elem Res 160(2):285–293
57. Sugie S, Tanaka T, El-Bayoumy K (2000) Chemoprevention of carcinogenesis by organoselenium compounds. J Health Sci 46(6):422–425
58. Whanger PD (2004) Selenium and its relationship to cancer: an update. Br J Nutr 91(1):11–28
59. Zhou N, Xiao H, Li TK, Nur EKA, Liu LF (2003) DNA damage-mediated apoptosis induced by selenium compounds. J Biol Chem 278(32):29532–29537
60. Jung HJ, Seo YR (2010) Current issues of selenium in cancer chemoprevention. Biofactors 36(2):153–158
61. Chintala S, Toth K, Cao S et al (2010) Se-methylselenocysteine sensitizes hypoxic tumor cells to irinotecan by targeting hypoxia-inducible factor 1 alpha. Cancer Chemother Pharmacol 66(5):899–911
62. Hu H, Li GX, Wang L, Watts J, Combs GF Jr, Lu J (2008) Methylseleninic acid enhances taxane drug efficacy against human prostate cancer and down-regulates antiapoptotic proteins Bcl-XL and survivin. Clin Cancer Res 14(4):1150–1158
63. Tan Q, Li J, Yin HW et al (2010) Augmented antitumor effects of combination therapy of cisplatin with ethaselen as a novel thioredoxin reductase inhibitor on human A549 cell in vivo. Invest New Drugs 28(3):205–215
64. Wei MX, Tamiya T, Chase M et al (1994) Experimental tumor therapy in mice using the cyclophosphamide-activating cytochrome P450 2B1 gene. Hum Gene Ther 5(8):969–978
65. Roy P, Yu LJ, Crespi CL, Waxman DJ (1999) Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles. Drug Metab Dispos 27(6):655–666
66. Fraiser LH, Kanekal S, Kehrer JP (1991) Cyclophosphamide toxicity. Characterising and avoiding the problem. Drugs 42(5):781–795
67. Chabra A, Shokrzadeh M, Naghshvar F, Salehi F, Ahmadi A (2014) Melatonin ameliorates oxidative stress and reproductive toxicity induced by cyclophosphamide in male mice. Hum Exp Toxicol 33(2):185–195
68. Das UB, Mallick M, Debnath JM, Ghosh D (2002) Protective effect of ascorbic acid on cyclophosphamide-induced testicular gametogenic and androgenic disorders in male rats. Asian J Androl 4(3):201–207
69. Ghosh D, Das UB, Ghosh S, Mallick M, Debnath J (2002) Testicular gametogenic and steroidogenic activities in cyclophosphamide treated rat: a correlative study with testicular oxidative stress. Drug Chem Toxicol 25(3):281–292
70. Manda K, Bhatia AL (2003) Prophylactic action of melatonin against cyclophosphamide-induced oxidative stress in mice. Cell Biol Toxicol 19(6):367–372
71. Korkmaz A, Topal T, Oter S (2007) Pathophysiological aspects of cyclophosphamide and ifosfamide induced hemorrhagic cystitis; implication of reactive oxygen and nitrogen species as well as PARP activation. Cell Biol Toxicol 23(5):303–312
72. Behrman HR, Preston SL (1989) Luteolytic actions of peroxide in rat ovarian cells. Endocrinology 124(6):2895–2900
73. Selvakumar E, Prahalathan C, Sudharsan PT, Varalakshmi P (2006) Chemoprotective effect of lipoic acid against cyclophosphamide-induced changes in the rat sperm. Toxicology 217(1):71–78
74. Tripathi DN, Jena GB (2008) Ebselen attenuates cyclophosphamide-induced oxidative stress and DNA damage in mice. Free Radic Res 42(11–12):966–977
75. Bhattacharjee A, Basu A, Ghosh P, Biswas J, Bhattacharya S (2014) Protective effect of Selenium nanoparticle against cyclophosphamide induced hepatotoxicity and genotoxicity in Swiss albino mice. J Biomater Appl 29(2):303–317
76. Kornblith PL, Walker M (1988) Chemotherapy for malignant gliomas. J Neurosurg 68(1):1–17
77. Kyritsis AP (1993) Chemotherapy for malignant gliomas. Oncology 7(9):93–100
78. Pech IV, Peterson K, Cairncross JG (1998) Chemotherapy for brain tumors. Oncology 12(4):537–543, 547
79. Ghorbani A, Omidvar B, Parsi A (2013) Protective effect of selenium on cisplatin induced nephrotoxicity: a double-blind controlled randomized clinical trial. J Nephropathol 2(2):129–134
80. Nematbakhsh M, Ashrafi F, Pezeshki Z et al (2012) A histopathological study of nephrotoxicity, hepatoxicity or testicular toxicity: which one is the first observation as side effect of Cisplatin-induced toxicity in animal model? J Nephropathol 1(3):190–193
81. Doz F, Pinkerton R (1994) What is the place of carboplatin in paediatric oncology? Eur J Cancer 30A(2):194–201
82. Calvert AH, Harland SJ, Newell DR et al (1982) Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II. Cancer Chemother Pharmacol 9(3):140–147
83. Foster BJ, Clagett-Carr K, Leyland-Jones B, Hoth D (1985) Results of NCI-sponsored phase I trials with carboplatin. Cancer Treat Rev 12(Suppl A):43–49
84. Cornelison TL, Reed E (1993) Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin. Gynecol Oncol 50(2):147–158
85. Pinzani V, Bressolle F, Haug IJ, Galtier M, Blayac JP, Balmes P (1994) Cisplatin-induced renal toxicity and toxicity-modulating strategies: a review. Cancer Chemother Pharmacol 35(1):1–9
86. Sahni V, Choudhury D, Ahmed Z (2009) Chemotherapy-associated renal dysfunction. Nat Rev Nephrol 5(8):450–462
87. Naziroglu M, Karaoğlu A, Aksoy AO (2004) Selenium and high dose vitamin E administration protects cisplatin-induced oxidative damage to renal, liver and lens tissues in rats. Toxicology 195:221–230
88. Chamberlain MC (2010) Temozolomide: Therapeutic limitations in the treatment of adult high-grade gliomas. Expert Rev Neurother 10(10):1537–1544
89. Omar AI, Mason WP (2010) Temozolomide: the evidence for its therapeutic efficacy in malignant astrocytomas. Core Evid 4:93–111
90. Chakravarti A, Erkkinen MG, Nestler U et al (2006) Temozolomide-mediated radiation enhancement in glioblastoma: a report on underlying mechanisms. Clin Cancer Res 12(15):4738–4746
91. Carmo A, Carvalheiro H, Crespo I, Nunes I, Lopes MC (2011) Effect of temozolomide on the U-118 glioma cell line. Oncol Lett 2(6):1165–1170
92. Gao S, Yang XJ, Zhang WG, Ji YW, Pan Q (2009) Mechanism of thalidomide to enhance cytotoxicity of temozolomide in U251-MG glioma cells in vitro. Chin Med J 122(11):1260–1266
93. Cheng Y, Sk UH, Zhang Y et al (2012) Rational incorporation of selenium into temozolomide elicits superior antitumor activity associated with both apoptotic and autophagic cell death. PLoS One 7(4):e35104
94. Letavayova L, Vlckova V, Brozmanova J (2006) Selenium: from cancer prevention to DNA damage. Toxicology 227(1–2):1–14
95. Biswas S, Talukder G, Sharma A (2000) Chromosome damage induced by selenium salts in human peripheral lymphocytes. Toxicol In Vitro 14(5):405–408
96. Letavayova L, Vlasakova D, Spallholz JE, Brozmanova J, Chovanec M (2008) Toxicity and mutagenicity of selenium compounds in Saccharomyces cerevisiae. Mutat Res 638(1–2):1–10
97. Wycherly BJ, Moak MA, Christensen MJ (2004) High dietary intake of sodium selenite induces oxidative DNA damage in rat liver. Nutr Cancer 48(1):78–83
98. Blot WJ, Li JY, Taylor PR et al (1993) Nutrition intervention trials in Linxian, China: supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population. J Natl Cancer Inst 85(18):1483–1492
99. Hercberg S, Galan P, Preziosi P et al (2004) The SU.VI.MAX Study: a randomized, placebo-controlled trial of the health effects of antioxidant vitamins and minerals. Arch Intern Med 164(21):2335–2342
100. Hercberg S, Ezzedine K, Guinot C et al (2007) Antioxidant supplementation increases the risk of skin cancers in women but not in men. J Nutr 137(9):2098–2105
101. Lippman SM, Klein EA, Goodman PJ et al (2009) Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 301(1):39–51
102. Goossens ME, Buntinx F, Joniau S et al (2012) Designing the selenium and bladder cancer trial (SELEBLAT), a phase lll randomized chemoprevention study with selenium on recurrence of bladder cancer in Belgium. BMC Urol 12:8